Robert Driscoll
Stock Analyst at Wedbush
(2.83)
# 1,649
Out of 5,122 analysts
156
Total ratings
36.23%
Success rate
0.34%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Driscoll
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TYRA Tyra Biosciences | Maintains: Outperform | $30 → $37 | $25.45 | +45.38% | 9 | Dec 16, 2025 | |
| CGON CG Oncology | Initiates: Outperform | $70 | $40.19 | +74.17% | 1 | Dec 11, 2025 | |
| CGEM Cullinan Therapeutics | Maintains: Outperform | $25 → $34 | $9.92 | +242.74% | 5 | Dec 9, 2025 | |
| KURA Kura Oncology | Maintains: Outperform | $36 → $38 | $10.22 | +271.82% | 11 | Nov 14, 2025 | |
| RVMD Revolution Medicines | Maintains: Outperform | $77 → $80 | $79.67 | +0.41% | 8 | Nov 6, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Outperform | $31 → $38 | $8.02 | +373.82% | 2 | Oct 20, 2025 | |
| REPL Replimune Group | Upgrades: Outperform | $4 → $18 | $9.82 | +83.30% | 7 | Oct 20, 2025 | |
| CBIO Crescent Biopharma | Initiates: Outperform | $27 | $11.60 | +132.76% | 1 | Jul 14, 2025 | |
| ZNTL Zentalis Pharmaceuticals | Reiterates: Neutral | $4 | $1.33 | +200.75% | 11 | May 15, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Outperform | $8 → $6 | $0.61 | +881.51% | 3 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $17 | $15.97 | +6.45% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $57 → $12 | $11.73 | +2.30% | 9 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $32 | $9.18 | +248.58% | 6 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $52 | $34.51 | +50.68% | 9 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $16 | $2.49 | +542.57% | 10 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $23.23 | +29.14% | 7 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $80 | $7.93 | +908.83% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $0.89 | +1,135.96% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $5.15 | +152.43% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $13 | $8.63 | +50.64% | 4 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $13.83 | +435.07% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $5.38 | +48.70% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $7 | $1.34 | +422.39% | 8 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $3 → $8 | $4.16 | +92.31% | 9 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2 → $4 | $4.62 | -13.42% | 4 | May 19, 2020 |
Tyra Biosciences
Dec 16, 2025
Maintains: Outperform
Price Target: $30 → $37
Current: $25.45
Upside: +45.38%
CG Oncology
Dec 11, 2025
Initiates: Outperform
Price Target: $70
Current: $40.19
Upside: +74.17%
Cullinan Therapeutics
Dec 9, 2025
Maintains: Outperform
Price Target: $25 → $34
Current: $9.92
Upside: +242.74%
Kura Oncology
Nov 14, 2025
Maintains: Outperform
Price Target: $36 → $38
Current: $10.22
Upside: +271.82%
Revolution Medicines
Nov 6, 2025
Maintains: Outperform
Price Target: $77 → $80
Current: $79.67
Upside: +0.41%
Corbus Pharmaceuticals Holdings
Oct 20, 2025
Maintains: Outperform
Price Target: $31 → $38
Current: $8.02
Upside: +373.82%
Replimune Group
Oct 20, 2025
Upgrades: Outperform
Price Target: $4 → $18
Current: $9.82
Upside: +83.30%
Crescent Biopharma
Jul 14, 2025
Initiates: Outperform
Price Target: $27
Current: $11.60
Upside: +132.76%
Zentalis Pharmaceuticals
May 15, 2025
Reiterates: Neutral
Price Target: $4
Current: $1.33
Upside: +200.75%
Werewolf Therapeutics
May 9, 2025
Maintains: Outperform
Price Target: $8 → $6
Current: $0.61
Upside: +881.51%
Mar 21, 2025
Maintains: Outperform
Price Target: $15 → $17
Current: $15.97
Upside: +6.45%
Mar 12, 2025
Downgrades: Neutral
Price Target: $57 → $12
Current: $11.73
Upside: +2.30%
Feb 26, 2025
Reiterates: Outperform
Price Target: $32
Current: $9.18
Upside: +248.58%
Dec 17, 2024
Reiterates: Outperform
Price Target: $52
Current: $34.51
Upside: +50.68%
Oct 8, 2024
Reiterates: Outperform
Price Target: $16
Current: $2.49
Upside: +542.57%
Oct 3, 2024
Reiterates: Outperform
Price Target: $30
Current: $23.23
Upside: +29.14%
Sep 20, 2024
Reiterates: Outperform
Price Target: $80
Current: $7.93
Upside: +908.83%
Aug 13, 2024
Reiterates: Outperform
Price Target: $11
Current: $0.89
Upside: +1,135.96%
Aug 9, 2024
Reiterates: Outperform
Price Target: $13
Current: $5.15
Upside: +152.43%
Aug 8, 2024
Maintains: Outperform
Price Target: $11 → $13
Current: $8.63
Upside: +50.64%
Aug 8, 2024
Reiterates: Outperform
Price Target: $74
Current: $13.83
Upside: +435.07%
Aug 7, 2024
Reiterates: Outperform
Price Target: $8
Current: $5.38
Upside: +48.70%
Jun 7, 2024
Reiterates: Outperform
Price Target: $7
Current: $1.34
Upside: +422.39%
May 9, 2024
Upgrades: Outperform
Price Target: $3 → $8
Current: $4.16
Upside: +92.31%
May 19, 2020
Upgrades: Outperform
Price Target: $2 → $4
Current: $4.62
Upside: -13.42%